Secukinumab 150 mg/mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 150 mg/mL
Reference Brands: Cosentyx
Category: Osteoporosis
Cosentyx (Secukinumab) 150 mg/mL is approved for psoriasis and arthritis. Available as autoinjector and syringe. Ideal for global pharma B2B supply.
Product Description:
Secukinumab (Cosentyx®) is a leading IL-17A monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is available as a 150 mg/mL prefilled syringe or autoinjector, designed for convenient subcutaneous administration. Trusted globally under the Cosentyx brand by Novartis, it is used in dermatology and rheumatology settings across the US and EU. Manufactured under GMP/ICH-compliant standards, Secukinumab is ideal for B2B pharmaceutical buyers, including hospitals, clinics, and specialty pharmacies. Contact us for bulk export, regulatory support, and competitive pricing.
Secukinumab — third party manufacturing & bulk supply
Secukinumab 150 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Secukinumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Secukinumab →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Secukinumab is used to treat autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It works by inhibiting interleukin-17A (IL-17A), a cytokine involved in inflammatory and immune responses.
Secukinumab is a fully human monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It specifically targets and binds to interleukin-17A, blocking its interaction with the IL-17 receptor.
The trade name of Secukinumab is Cosentyx.
Secukinumab is developed and manufactured by Novartis Pharmaceuticals.
The generic name is Secukinumab.
The brand name is Cosentyx.
Secukinumab is primarily manufactured by Novartis in Switzerland and other global manufacturing facilities that follow international GMP standards.
Related Products
Abaloparatide
Strength:
80 mcg
Form: injection (prefilled syringe)
Reference Brands: Tymlos (USA), Eladynos (EU)
View Details
Pamidronate Disodium
Strength:
15 mg, 30 mg, 60 mg, 90 mg
Form: Injection
Reference Brands: Aredia (USA/EU)
View Details
Calcitonin Salmon
Strength:
100 IU/mL, 200 IU/mL
Form: Injection / nasal spray
Reference Brands: Fortical (USA), Miacalcin (USA)
View DetailsQuick Response Guaranteed | Verified Suppliers
